Intellizon Medical, a Suzhou-based developer of implantable brain-computer interfaces, has raised nearly 100 million yuan, about $14 million, in a Pre-A+ funding round, according to PEdaily. The round was jointly led by Fuhui Capital and Fuyong Investment, with Songhe Capital and Beijing Industrial Investment joining as follow-on backers. Starbridge Capital is serving as exclusive financial advisor for future rounds. The deal was announced November 19, 2026.
What is a brain-spine interface, exactly?
Intellizon's core product is what it calls a BSI, or brain-spine interface: an implantable device that reads electrical signals from the brain and writes stimulation signals to the spinal cord, forming a closed loop meant to restore movement after injury. The platform is bidirectional, meaning it both records neural activity and delivers targeted stimulation, and modular, so the same hardware can be reconfigured for different patients and conditions. The company says it developed the stack end to end in-house, covering electrodes, sensors, custom chips, packaging, signal processing and the AI algorithms that decode neural data in real time.
Engineering highlights the company points to include high-throughput signal acquisition, independently programmable stimulation across multiple targets, low-latency closed-loop response, wireless power delivery so patients don't need external battery packs, and MRI compatibility, a feature that matters because many implant recipients eventually need imaging for unrelated care. The primary clinical target is restoring motor function after spinal cord injury or stroke.
How does this fit the broader neurotech and medical robotics landscape?
Implantable BCIs sit at the intersection of medical robotics and physical AI: the device has to sense the body's own signals, interpret them with onboard algorithms, and act on the nervous system in near real time, the same sense-think-act loop that defines robotics more broadly. Intellizon's bidirectional, closed-loop approach distinguishes it from BCI efforts that only read brain signals for communication purposes, since it is actively trying to restore physical movement rather than just decode intent for a cursor or speech output.
The company says its non-invasive and consumer-facing neurotech products have already seen partial commercialization, giving it some revenue before this implant reaches market. That revenue base is relatively unusual for an early-stage BCI company and may have helped it secure follow-on investors beyond its lead backers.
What will the money fund, and what comes next?
The capital is earmarked for three things: pushing the core BSI device into formal clinical trials, scaling manufacturing of the modular implantable platform toward mass production, and expanding research into new applications including language decoding, visual restoration for blindness, and depression treatment. Each of those adjacent applications would require separate regulatory pathways, so near-term progress will likely be judged by how quickly the spinal cord injury and stroke trials advance.
Watch for Intellizon to disclose trial enrollment numbers or a regulatory filing timeline in China, where several domestic BCI developers are racing toward clinical approval. The next funding milestone, given Starbridge Capital's advisory mandate, is likely a larger Series A once clinical data starts coming in.